A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH
Status:
Completed
Trial end date:
2019-08-08
Target enrollment:
Participant gender:
Summary
PB1046-PT-CL-0005 is an open-label, dose-titration study to assess the safety, tolerability,
and hemodynamic effects of individually dose-titrated PB1046 administered by weekly
subcutaneous injection for 8 weeks in adult subjects with PAH who have a permanently
implanted hemodynamic monitor in the distal pulmonary artery. The primary objectives of the
study are to assess the overall safety, tolerability, and hemodynamic profile of a PB1046
across an individually titrated dose range.